Dilemma of first line regimens in metastatic pancreatic adenocarcinoma

Pancreatic cancer is one of the deadliest cancers, ranking fourth among cancer-related deaths. Despite all the major molecular advances and treatment breakthroughs, mainly targeted therapies, the cornerstone treatment of metastatic pancreatic cancer (mPC) remains cytotoxic chemotherapy. In 2016, mor...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghosn, Marwan, Ibrahim, Tony, Assi, Tarek, El Rassy, Elie, Kourie, Hampig Raphael, Kattan, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2016
Materias:
Minireviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5155171/
https://www.ncbi.nlm.nih.gov/pubmed/28028360
http://dx.doi.org/10.3748/wjg.v22.i46.10124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5155171/
https://www.ncbi.nlm.nih.gov/pubmed/28028360
http://dx.doi.org/10.3748/wjg.v22.i46.10124

Ejemplares similares